LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses

Medicine, Rheumatology and Immunology, Oncology, Life Sciences, Cell Biology, Immunology,
LRIG1   VISTA   tumor-specific   CD8+ T cells   immune checkpoint   anti-tumor immunity   immunotherapy  

Immunotherapy Checkpoint Inhibitors (ICIs, also known as immune checkpoint blockers) are a class of drugs that have achieved significant breakthroughs in cancer immunotherapy in recent years. These drugs mainly work by blocking Programmed Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4), thereby activating anti-tumor ...

Intratumoral Antigen Signaling Traps CD8+ T Cells to Confine Exhaustion to the Tumor Site

Medicine, Rheumatology and Immunology, Oncology, Life Sciences, Immunology,
cancer immunology   CD8+ T cells   antigen signaling   clonal expansion   T cell exhaustion  

Tumor Immunology Research: The Exhausted State of CD8+ T Cells in Tumors In recent years, immunotherapy has achieved significant progress in the field of tumor treatment. However, tracking the behavior of lymphocytes following antigen signals remains challenging. This study aims to address this issue by developing Antigen Receptor Signaling Reporte...